O
Oyewale O. Abidoye
Researcher at Genentech
Publications - 15
Citations - 4792
Oyewale O. Abidoye is an academic researcher from Genentech. The author has contributed to research in topics: Atezolizumab & Metastatic Urothelial Carcinoma. The author has an hindex of 10, co-authored 15 publications receiving 3770 citations.
Papers
More filters
Journal ArticleDOI
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg,Jean H. Hoffman-Censits,Thomas Powles,Michiel S. van der Heijden,Arjun Vasant Balar,Andrea Necchi,Nancy A. Dawson,Peter H. O'Donnell,Ani Balmanoukian,Yohann Loriot,Sandy Srinivas,Margitta Retz,Petros Grivas,Richard W. Joseph,Matthew D. Galsky,Mark D. Fleming,Daniel P. Petrylak,Jose Luis Perez-Gracia,Howard A. Burris,Daniel Castellano,Christina Canil,Joaquim Bellmunt,Dean F. Bajorin,Dorothee Nickles,Richard Bourgon,Garrett M. Frampton,Na Cui,Sanjeev Mariathasan,Oyewale O. Abidoye,Gregg Fine,Robert Dreicer +30 more
TL;DR: Treatment with atezolizumab resulted in a significantly improved RECIST v1.1 response rate, compared with a historical control overall response rate of 10%, and Exploratory analyses showed The Cancer Genome Atlas (TCGA) subtypes and mutation load to be independently predictive for response to atezolediazepine.
Journal ArticleDOI
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Arjun Vasant Balar,Matthew D. Galsky,Jonathan E. Rosenberg,Thomas Powles,Daniel P. Petrylak,Joaquim Bellmunt,Yohann Loriot,Andrea Necchi,Jean H. Hoffman-Censits,Jose Luis Perez-Gracia,Nancy A. Dawson,Michiel S. van der Heijden,Robert Dreicer,Sandy Srinivas,Margitta Retz,Richard W. Joseph,Alexandra Drakaki,Ulka N. Vaishampayan,Srikala S. Sridhar,David I. Quinn,Ignacio Duran,David R. Shaffer,Bernhard J. Eigl,Petros Grivas,Evan Y. Yu,S. Li,Edward E. Kadel,Zachary Boyd,Richard Bourgon,Priti S. Hegde,Sanjeev Mariathasan,Ann Christine Thastrom,Oyewale O. Abidoye,Gregg Fine,Dean F. Bajorin +34 more
TL;DR: Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer.
Journal ArticleDOI
A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).
Daniel P. Petrylak,Thomas Powles,Joaquim Bellmunt,Fadi Braiteh,Yohann Loriot,Cristina Cruz Zambrano,Howard A. Burris,Joseph Kim,Siew-leng Melinda Teng,Jean-Marie Bruey,Priti S. Hegde,Oyewale O. Abidoye,Nicholas J. Vogelzang +12 more
TL;DR: PD-L1 may contribute to immune escape in UBC, a disease of high mutational complexity and immunogenicity and MPDL3280A was designed to restore T cell–mediated antitumor activity by restoring PD-L 1 activity.
Journal ArticleDOI
IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).
Jean H. Hoffman-Censits,Petros Grivas,Michiel S. van der Heijden,Robert Dreicer,Yohann Loriot,Margitta Retz,Nicholas J. Vogelzang,Jose Luis Perez-Gracia,Arash Rezazadeh,Sergio Bracarda,Evan Y. Yu,Christopher J. Hoimes,Joaquim Bellmunt,David I. Quinn,Daniel P. Petrylak,Syed A. Hussain,Na Cui,Sanjeev Mariathasan,Oyewale O. Abidoye,Jonathan E. Rosenberg +19 more
TL;DR: Efficacy/safety-evaluable pts had a median age of 66 y, CrCl < 60 mL/min (35%) and ≥ 2 prior regimens for mUC (40%).
Journal ArticleDOI
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
Hope S. Rugo,Adam Brufsky,Marianne Ulcickas Yood,Debasish Tripathy,Peter A. Kaufman,Musa Mayer,Bongin Yoo,Oyewale O. Abidoye,Denise A. Yardley +8 more
TL;DR: For example, the authors found that the risk of cardiac safety events (grade ≥ 3) was higher in black patients (10.9% vs. white patients (7.9%).